Shire PLC Company Profile (LON:SHP)

About Shire PLC

Shire PLC logoShire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. The Company's products include VYVANSE/VENVANSE/ELVANSE/TYVENSE/ELVANSEVUXEN/ADUVANZ (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), LIALDA (mesalamine)/MEZAVANT(mesalazine), PENTASA (mesalamine), REPLAGAL (agalsidase alfa), ELAPRASE (idursulfase), VPRIV (velaglucerase alfa), FIRAZYR (icatibant), FOSRENOL (lanthanum carbonate), KALBITOR, CINRYZE C1 esterase inhibitor (human), GATTEX/REVESTIVE, BUMINATE 25% Albumin (Human), BUMINATE 5% Albumin (Human), GLASSIA Alpha1-Proteinase Inhibitor (Human) and ONCASPAR pegaspargase.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: LON
  • Symbol: SHP
  • CUSIP:
Key Metrics:
  • Previous Close: $59.63
  • 50 Day Moving Average: $5050.14
  • 200 Day Moving Average: $4657.21
  • 52-Week Range: GBX 2,707.19 - GBX 5,562.83
  • Trailing P/E Ratio: 30.50
  • P/E Growth: 0.89
  • Market Cap: $33.41B
  • Outstanding Shares: 682,799,000
Additional Links:

Analyst Ratings

Consensus Ratings for Shire PLC (LON:SHP) (?)
Ratings Breakdown: 1 Sell Rating, 18 Buy Ratings
Consensus Rating:Buy (Score: 2.89)
Consensus Price Target: GBX 5,881.33

Analysts' Ratings History for Shire PLC (LON:SHP)
DateFirmActionRatingPrice TargetDetails
10/24/2016JPMorgan Chase & Co.Reiterated RatingOverweightView Rating Details
10/24/2016Bryan, Garnier & CoReiterated RatingBuyGBX 6,900View Rating Details
10/20/2016BNP ParibasReiterated RatingOutperformGBX 5,900View Rating Details
10/19/2016Jefferies GroupReiterated RatingOverweightGBX 6,300View Rating Details
10/12/2016Deutsche Bank AGReiterated RatingBuyGBX 6,200View Rating Details
10/12/2016Goldman Sachs Group Inc.Reiterated RatingBuyGBX 6,300View Rating Details
10/7/2016Credit Suisse Group AGReiterated RatingOutperformGBX 5,200View Rating Details
10/6/2016Shore CapitalReiterated RatingBuyView Rating Details
9/28/2016HSBCLower Price Target HoldGBX 5,250 -> GBX 5,200View Rating Details
9/27/2016Berenberg BankReiterated RatingBuyGBX 5,800View Rating Details
9/27/2016Citigroup Inc.Reiterated RatingBuyView Rating Details
9/19/2016Liberum CapitalReiterated RatingBuyGBX 5,500View Rating Details
8/3/2016Royal Bank Of CanadaReiterated RatingOutperformView Rating Details
6/3/2016Morgan StanleyReiterated RatingOverweightGBX 5,600View Rating Details
3/15/2016Sanford C. BernsteinReiterated RatingOutperformGBX 5,000View Rating Details
3/10/2016AlphaValueReiterated RatingBuyGBX 6,420View Rating Details
1/12/2016S&P Equity ResearchReiterated RatingBuyView Rating Details
1/5/2016Barclays PLCReiterated RatingOverweightGBX 5,700View Rating Details
12/3/2015InvestecDowngradeSellView Rating Details
11/3/2015Kepler Capital MarketsLower Price TargetBuyGBX 6,000 -> GBX 5,900View Rating Details
10/19/2015Bank of America Corp.Reiterated RatingNeutralGBX 6,000View Rating Details
5/18/2015XYZ ResearchReiterated RatingOutperformGBX 6,600View Rating Details
4/30/2015Charles StanleyReiterated RatingaccumulateView Rating Details
(Data available from 10/25/2014 forward)


Earnings History for Shire PLC (LON:SHP)
No earnings announcements for this company have been tracked by


Earnings Estimates for Shire PLC (LON:SHP)
Current Year EPS Consensus Estimate: $4.33 EPS


Dividend History for Shire PLC (LON:SHP)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/2/2016GBX 3.510.07%9/8/20169/8/201610/7/2016
2/11/2016GBX 15.320.44%3/10/20163/10/20164/12/2016
7/23/2015GBX 2.690.05%9/3/20159/3/201510/2/2015
7/18/2014GBX 2.240.04%9/3/20149/3/201410/3/2014
2/13/2014GBX 10.210.31%3/5/20143/5/20144/8/2014
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Shire PLC (LON:SHP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/30/2016Dominic BlakemoreInsiderBuy133GBX 5,010£6,663.30
6/30/2016Bohuon,OlivierInsiderBuy134GBX 4,463£5,980.42
3/31/2016Bohuon,OlivierInsiderBuy133GBX 3,908£5,197.64
2/15/2016Bohuon,OlivierInsiderBuy1,000GBX 3,552£35,520
2/12/2016Burns,WilliamInsiderBuy1,250GBX 3,563£44,537.50
12/18/2015Burns,WilliamInsiderBuy156GBX 4,457£6,952.92
9/30/2015Blakemore ,DominicInsiderBuy129GBX 4,498£5,802.42
6/30/2015Kappler,David JInsiderBuy126GBX 51.05GBX 6,432.30
3/31/2015Susan KilsbyInsiderBuy375GBX 5,327£19,976.25
12/19/2014Steven GillisInsiderBuy228GBX 4,654£10,611.12
10/30/2014Steven GillisInsiderBuy381GBX 4,098£15,613.38
(Data available from 1/1/2013 forward)


Latest Headlines for Shire PLC (LON:SHP)
News IconShire unveils powerful spoken word video to raise awareness of some of the issues many adults with ADHD face (LON:SHP) - October 25 at 12:32 PM logoShire Plc breached its 50 day moving average in a Bearish Manner : SHP-GB : October 25, 2016 (LON:SHP) - October 25 at 12:32 PM
News IconAhead of Shire plc 3Q16 Results, Exane BNP Paribas Maintains Outperform Rating - Analyst Ratings (LON:SHP) - October 23 at 11:29 AM logoShire Granted EU Marketing Authorization of Onivyde®, in Combination With 5-Fluorouracil (5-FU) and Leucovorin … (LON:SHP) - October 18 at 12:38 PM logoShire Granted EU Marketing ... (LON:SHP) - October 18 at 12:38 PM logoPharmaEngine Announces Onivyde(R) Receives European Marketing Authorization for the Treatment of Metastatic Adenocarcinoma of the Pancreas Following Gemcitabine based Therapy (LON:SHP) - October 18 at 12:38 PM logoShire (SHPG) Updates Vyvanse Label with New Efficacy Data (LON:SHP) - October 18 at 12:38 PM
News IconModern Technology and a Multi-Screen Lifestyle Viewed as Important Factors in Rising Prevalence of Dry Eye Disease (LON:SHP) - October 17 at 12:35 PM logoShire Announces Update to Vyvanse® (lisdexamfetamine dimesylate) U.S. Labeling to Include New Longer-Term … (LON:SHP) - October 17 at 12:35 PM logoModern Technology and a ... (LON:SHP) - October 17 at 12:35 PM
News IconDeutsche Bank AG Reiterates “Buy” Rating for Shire PLC (SHP) - DailyQuint (LON:SHP) - October 15 at 12:01 PM
News IconResearch Analysts' Recent Ratings Updates for Shire PLC (SHP) - DailyQuint (LON:SHP) - October 11 at 8:11 PM logoFinal Results of NAPOLI-1 Study Confirm Overall Survival and Progression-Free Survival Benefit for the ONIVYDE® Regimen for Patients with Metastatic Pancreatic Cancer (LON:SHP) - October 11 at 2:16 PM logoPatent Trial And Appeal Board Upholds Validity Of Shire's LIALDA Patent (LON:SHP) - October 6 at 7:02 PM
News IconKamada Announces Extension of GLASSIA® Supply and Distribution Agreement with Shire with Minimum $237 Million of Revenue for the Years 2017 to 2020 (LON:SHP) - October 6 at 12:54 PM logoKamada To Produce GLASSIA For Shire Through 2020 - Quick Facts (LON:SHP) - October 6 at 12:54 PM logoSHIRE PLC : - Director/PDMR Shareholding (LON:SHP) - September 30 at 2:30 PM logoShire: Not a dry eye in the house (LON:SHP) - September 29 at 12:42 PM logoDo today's results make this company a better buy than Shire plc? - Motley Fool UK (LON:SHP) - September 26 at 7:20 PM logoShire : Closes Public Offering of Senior Notes (LON:SHP) - September 23 at 11:57 AM
News IconShire PLC's Buy Rating Reiterated at Berenberg Bank (SHP) - Petro Global News 24 (LON:SHP) - September 22 at 12:06 PM logoU.K. stocks higher at close of trade; United Kingdom 100 up 0.25% (LON:SHP) - September 21 at 11:22 AM logoAre these top healthcare stocks in your portfolio? (LON:SHP) - September 21 at 11:22 AM logoShire Prices Public Offering Of Senior Notes - Quick Facts - Nasdaq (LON:SHP) - September 20 at 12:37 PM
News IconShire PLC (SHP) Price Target Raised to GBX 6050 at Jefferies Group - DailyQuint (LON:SHP) - September 20 at 12:37 PM logoOrder book for Shire's M&A bond reach US$25bn: lead (LON:SHP) - September 19 at 11:51 AM logoDistrict Court Issues Ruling in Hatch Waxman Case Regarding Shire's LIALDA® - Yahoo Finance (LON:SHP) - September 18 at 6:45 PM
News IconShire PLC (SHP) Earns Buy Rating from HSBC | NewsDen - NewsDen (LON:SHP) - September 17 at 6:45 PM logoDistrict Court Issues Ruling in Hatch Waxman Case Regarding Shire's LIALDA® - PR Newswire (press release) (LON:SHP) - September 16 at 7:00 PM
News IconShire Announces FDA Approval of Cuvitru [immune globulin subcutaneous (human)] for Primary Immunodeficiency (LON:SHP) - September 16 at 10:51 AM
News IconShire Announces U.S. FDA Approval of CUVITRU[TM] [Immune Globulin Subcutaneous (Human), 20% Solution] Treatment for Primary Immunodeficiency (LON:SHP) - September 15 at 7:23 PM logoShire Announces U.S. FDA Approval of CUVITRU[TM] [Immune Globulin Subcutaneous (Human), 20% Solution ... - PR Newswire (press release) (LON:SHP) - September 15 at 10:56 AM
News IconNetplay TV Plc (NPT) to Issue GBX 0.22 Dividend (LON:SHP) - September 14 at 7:27 PM
News IconShire Announces U.S. FDA Approval of CUVITRUTM [Immune Globulin Subcutaneous (Human), 20% Solution] Treatment for Primary Immunodeficiency (LON:SHP) - September 14 at 7:27 PM
News IconShire Plc (SHP) - Medical Equipment - Deals and Alliances Profile - New Market Research Report (LON:SHP) - September 14 at 7:27 PM logoShire PLC 41.7% Potential Upside Indicated by Jefferies International - DirectorsTalk Interviews (LON:SHP) - September 12 at 6:51 PM
News IconShire Plc (LON:SHP) Receives Buy Rating From Jefferies Analysts - National Daily Press (LON:SHP) - September 12 at 6:51 PM
News IconShire to Participate at Two Upcoming Investor Conferences - PR Newswire UK (press release) (LON:SHP) - September 8 at 6:58 PM logoShire to Participate at Two Upcoming Investor Conferences - PR Newswire (press release) (LON:SHP) - September 8 at 11:07 AM logo[$$] Companies race to sell corporate debt in test of investor appetite (LON:SHP) - September 6 at 7:26 PM
News IconHot Biotech Stocks Recap: Achillion Pharmaceuticals (NASDAQ:ACHN), Merrimack Pharmaceuticals (NASDAQ:MACK) - The Voice Registrar (LON:SHP) - September 6 at 12:01 PM
News IconSHIRE PLC - U.S. Securities and Exchange Commission filings (LON:SHP) - September 5 at 6:24 PM
News IconDechra Pharmaceuticals plc Still Leads GlaxoSmithKline plc ... - Investomania (blog) (LON:SHP) - September 5 at 11:22 AM logoUK shares close lower, wary of Fed speech, pharma dragged down by Clinton remarks (LON:SHP) - August 25 at 7:39 PM logoMylan boss take the fight to Hillary (LON:SHP) - August 25 at 12:30 PM logoShire leads the fallers as £3.7bn is wiped from drugs sector after Clinton blast (LON:SHP) - August 25 at 12:30 PM logoETF’s with exposure to Shire Plc : August 24, 2016 (LON:SHP) - August 24 at 7:06 PM logoShire Plc :SHP-GB: Earnings Analysis: Q2, 2016 By the Numbers : August 23, 2016 (LON:SHP) - August 23 at 11:55 AM logoShire : Elections for the interim dividend (LON:SHP) - August 19 at 7:15 PM
News IconSHIRE PLC - Elections for the interim dividend (LON:SHP) - August 19 at 7:15 PM


Last Updated on 10/25/2016 by Staff